Trials / Completed
CompletedNCT01293422
Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis
PXR-aktivaation Vaikutukset Sokeri-, Kolesteroli- ja Hormonitasapainoon
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- University of Oulu · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This clinical trial is designed to study the effects of pregnane X receptor activator rifampicin on the glucose, lipid and hormone homeostasis in healthy volunteers. The main hypothesis is that rifampicin raises postprandial glucose studied with oral glucose tolerance test. The study is a non-randomized, one-phase, open-label trial. Twelve subjects will be given 600 mg of rifampicin a day for a week. The main outcome measures are the changes in the glucose and insulin levels during oral glucose tolerance test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifampicin | Rifampicin 600 mg daily for a week |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2011-02-10
- Last updated
- 2012-09-10
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT01293422. Inclusion in this directory is not an endorsement.